Scribd Logo
Upload

Welcome to Scribd!

  • 40 views

    SPARCtool

    Uploaded by

    qerat88
    Sparc is a tool for estimating stroke risk and benefits/risks of antithrombotic therapy in patients with atrial fibrillation. It was developed by Peter Loewen of the University of British Columbia. The tool calculates the patient's CHA2DS2-VASc score to determine their annual stroke risk and HAS-BLED score to determine their annual major bleeding risk. It then provides the annual risks of stroke/embolism and major bleeding for different therapy options to help determine the option with the highest net clinical benefit.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    SPARCtool

    Uploaded by

    qerat88
    40 views1 page
    Sparc is a tool for estimating stroke risk and benefits/risks of antithrombotic therapy in patients with atrial fibrillation. It was developed by Peter Loewen of the University of British Columbia. The tool calculates the patient's CHA2DS2-VASc score to determine their annual stroke risk and HAS-BLED score to determine their annual major bleeding risk. It then provides the annual risks of stroke/embolism and major bleeding for different therapy options to help determine the option with the highest net clinical benefit.

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Sparc is a tool for estimating stroke risk and benefits/risks of antithrombotic therapy in patients with atrial fibrillation. It was developed by Peter Loewen of the University of British Columbia. The tool calculates the patient's CHA2DS2-VASc score to determine their annual stroke risk and HAS-BLED score to determine their annual major bleeding risk. It then provides the annual risks of stroke/embolism and major bleeding for different therapy options to help determine the option with the highest net clinical benefit.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    40 views1 page

    SPARCtool

    Uploaded by

    qerat88
    Sparc is a tool for estimating stroke risk and benefits/risks of antithrombotic therapy in patients with atrial fibrillation. It was developed by Peter Loewen of the University of British Columbia. The tool calculates the patient's CHA2DS2-VASc score to determine their annual stroke risk and HAS-BLED score to determine their annual major bleeding risk. It then provides the annual risks of stroke/embolism and major bleeding for different therapy options to help determine the option with the highest net clinical benefit.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    mobile version (http://www.sparctool.

    com/mobile)

    SPARC - Stroke Prevention in Atrial Fibrillation Risk Tool


    for estimating risk of stroke and benefits & risks of antithrombotic therapy in patients with chronic atrial fibrillation

    Developed by Peter Loewen, ACPR, Pharm.D., FCSHP [email protected]


    (mailto:[email protected])
    references/notes
    version 9, May 2019
    (http://www.sparctool.com/sparcnotes.htm)
    DISCLAIMER: this tool may be used unaltered for learning purposes and the author assumes no responsibility whatsoever for any
    decisions or harms to anyone resulting from its use. The author makes no representations, conditions or warranties, either express or
    implied, regarding this tool.

    Patient:
    Date: Tuesday, March 03, 2020 0

    In your patient with atrial fibrillation, which of the following stroke or bleeding risk factors are present?
    0

    Stroke Risk (CHA2DS2-VASc)  Reset 00

    Age <65 65-74 75+ 0 0

    TIA or stroke CHF/LV dysfunction


    0
    (at any time in the past) (diagnosed at any time in the past)
    Prior MI, peripheral artery disease, or Hypertension
    0
    aortic plaque (controlled or uncontrolled)
    Diabetes Type I or II
    Female 0
    (controlled or uncontrolled)
    CHA2DS2-VASc SCORE (0-9): 0
    Major Bleeding Risk (HAS-BLED)
    Abnormal renal function History of labile INR
    (dialysis, SCr>200 mcmol/L, or transplant) (time in therapeutic range <60%) 00
    Hypertension Current use of alcohol
    (SBP>160mmHg) (>8 drinks per week) 00
    Abnormal liver function
    Currently taking antiplatelet drug or NSAID
    (cirrhosis or liver enzymes >3x ULN) 00
    History of major bleeding
    HAS-BLED SCORE (0-9): 0
    (any cause) 0

    Which therapy options to HIDE?

    Aspirin Dabigatran

    Aspirin+Clopidogrel Rivaroxaban Hide stroke/bleed chart

    Warfarin Apixaban Hide net clin benefit chart

    Edoxaban

    PERCENT PER YEAR


    annual risk of major bleeding (intracranial
    annual risk of bleeding, bleeding requiring hospitalization,
    stroke/embolism HgB decrease of > 20 g/L, or need for
    Net clinical benefit transfusion secondary to bleeding)

    N/A NO THERAPY 0.7% 0.3%

    You might also like